Showing 1 – 20 of 1044
Relevance | Newest | Oldest |
  • Intravenous Lymphoma Drug Approved

    Abstract Full Text
    JAMA. 2017; 318(17):1644-1644. doi: 10.1001/jama.2017.16047
  • Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

    Abstract Full Text
    is active quiz
    JAMA. 2017; 318(17):1679-1686. doi: 10.1001/jama.2017.16071

    This pharmacoepidemiology study conducted in France assesses the risk of lymphoma associated with thiopurines and anti–tumor necrosis factor agents, used alone or in combination, for treatment of inflammatory bowel disease.

  • New Leukemia, Lymphoma Diagnostic

    Abstract Full Text
    JAMA. 2017; 318(7):604-604. doi: 10.1001/jama.2017.10283
  • JAMA November 22, 2016

    Figure 3: Random-Effects Meta-analysis of Randomized Clinical Trials on the Association Between Palliative Care and Patient Quality of Life at 4- to 6-Month Follow-Up

    For all trials, the P value for the pooled standardized mean difference (SMD) was .12; τ2, 0.04; and Q, 28.51. For trials at high risk of bias, the P value for the pooled the SMD was .07; τ2, <0.06; and Q, 9.15. For trials at low risk of bias, the P value for the pooled SMD was .01; τ2 <0.0001; Q, 3.20. For trials at unclear risk of bias, the P value for the pooled SMD was .41; τ2, 0.05; and Q, 4.86. Sample sizes in the figure are the number of patients analyzed at the specific time points.Error bars represent 95% CIs. The size of the shaded squares indicates study weight. Diamonds represent pooled SMDs and 95% CIs. The vertical dashed line indicates the pooled effect estimate, and the solid vertical line depicts a null effect. EQ-5D indicates EuroQol 5 Dimensions Questionnaire; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT-Pal, Functional Assessment of Chronic Illness Therapy-Palliative; FACIT-Sp, Functional Assessment of Chronic Illness Therapy-Spirituality; HIV, human immunodeficiency virus; MOS-HIV, Medical Outcomes Study-HIV scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; and SF-36, Short Form-36. aBrain, gastrointestinal, head-neck, lung, and other cancers. bBreast, colon, lung, and gynecological cancers, and lymphoma. cBreast cancer. dUpper gastrointestinal cancers.eGastrointestinal, lung, genitourinary, and breast cancers. fProstate cancer. gNot further specified. hLung, gastrointestinal, genitourinary, breast, and gynecological cancers. iBreast, colon, lung, and prostate cancers.
  • JAMA November 22, 2016

    Figure 4: Meta-analysis of Randomized Clinical Trials on the Association Between Palliative Care and Symptom Burden at 1- to 3-Month Follow-up

    For all trials, the P value for the pooled standardized mean difference (SMD) was .03; τ2, 0.86; and Q, 230.90. For trials at high risk of bias, the P value for the pooled the SMD was .14; τ2, 2.34; and Q, 215.72. For trials at unclear risk of bias, the P value for the pooled SMD was .01; τ2, <0.0001; and Q, 230.90. Sample sizes in the figure are the number of patients analyzed at the specific time points.Error bars represent 95% CIs. The size of the shaded squares indicates study weight. Diamonds represent pooled SMDs and 95% CIs. The vertical dashed line indicates the pooled effect estimate, and the solid vertical line depicts a null effect. CHFQ indicates Chronic Heart Failure Questionnaire; COPD, chronic obstructive pulmonary disease; ESAS, Edmonton Symptom Assessment Scale; FACT-L LCS, Functional Assessment of Cancer Therapy-Lung Lung Cancer Scale; NRS SOB, Numerical Rating Scale Shortness of Breath; POS, Palliative Outcomes Scale; QUAL-E, Quality of Life at the End of Life; and SES, Symptom Experience Scale.aSolid or hematological cancers. bCOPD or other source of dyspnea. cBreast, colon, lung, and gynecological cancers, and lymphoma. dGastrointestinal, lung, genitourinary, and breast cancers. eCancer, COPD, heart failure, interstitial lung disease, motor neuron disease. fNon–small cell lung cancer. gLung, gastrointestinal, genitourinary, breast, and gynecological cancers.
  • JAMA November 22, 2016

    Figure 5: Meta-analysis of Randomized Clinical Trials on the Association Between Palliative Care and Symptom Burden at 4- to 6-Month Follow-up

    For all trials, the P value for the pooled standardized mean difference (SMD) was .01; τ2, <0.0001; and Q, 3.97. For trials at low risk of bias, the P value for the pooled the SMD was .06; τ2, <0.0001; and Q, 0.62. For trials at high risk of bias, the P value for the pooled SMD was .01; τ2, <0.0001; and Q, 0.31. Sample sizes in the figure are the number of patients analyzed at the specific time points.Error bars represent 95% CIs. The size of the shaded squares indicates study weight. Diamonds represent pooled SMDs and 95% CIs. The vertical dashed line indicates the pooled effect estimate, and the solid vertical line depicts a null effect. APOS indicates African Palliative Outcomes Scale; BPI, Brief Pain Inventory; ESAS, Edmonton Symptom Assessment Scale; HF, heart failure; HIV, human immunodeficiency virus; MS, multiple sclerosis; OSQ, Omega Symptom Questionnaire; and SES, Symptom Experience Scale.aBreast, colon, lung, and gynecological cancers and lymphoma. bUpper gastrointestinal cancers. cGastrointestinal, lung, genitourinary, and breast cancers. dProstate cancer. eLung, gastrointestinal, genitourinary, breast, and gynecological cancers.
  • JAMA November 22, 2016

    Figure 2: Random-Effects Meta-analysis of Randomized Clinical Trials on the Association Between Palliative Care and Patient Quality of Life at 1- to 3-Month Follow-up

    For all trials, the P value for the pooled standardized mean difference (SMD) was .02; τ2, 0.52; and Q, 268.18. For trials at low risk of bias, the P value for the pooled the SMD was .01; τ2, <0.0001; and Q, 3.36. For trials at high risk of bias, the P value for the pooled SMD was .05; τ2, 1.52; and Q, 233.84. For trials at unclear risk of bias, the P value for the pooled SMD was .31; τ2, 0.01; and Q, 3.00. Sample sizes in the figure are the number of patients analyzed at the specific time points. Error bars represent 95% CIs. The size of the shaded squares indicates study weight. Diamonds represent pooled SMDs and 95% CIs. The vertical dashed line indicates the pooled effect estimate, and the solid vertical line depicts a null effect. SF-36 indicates Short Form-36; EQ5D, EuroQol 5 Dimensions Questionnaire; FACIT-Pal, Functional Assessment of Chronic Illness Therapy–Palliative; FACT-L TOI, Functional Assessment of Cancer Therapy–Lung Treatment Outcome Index; FACT-G, Functional Assessment of Cancer Therapy- General; FACIT-Sp, Functional Assessment of Chronic Illness Therapy-Spirituality; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHFQ, Minnesota Living With Heart Failure Questionnaire; and MQOL-HK, McGill Quality of Life Questionnaire–Hong Kong adaptation.aSolid or hematological cancers. bBrain, gastrointestinal, head-neck, lung, and other cancers. cBreast, colon, lung, and gynecological cancers, and lymphoma. dNot further specified. eBreast cancer.fGastrointestinal, lung, genitourinary, and breast cancers. gCancer, chronic obstructive pulmonary disease, interstitial lung disease, and motor neuron disease. hNon–small cell lung cancer. iLung, gastrointestinal, genitourinary, breast, and gynecological cancers. jBreast, colon, lung, and other cancers. kBreast, colon, lung, and prostate cancers.
  • Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial

    Abstract Full Text
    free access is active quiz
    JAMA. 2016; 316(20):2094-2103. doi: 10.1001/jama.2016.16786

    This randomized trial assesses the effect of an inpatient palliative care intervention vs standard transplant care on quality of life during hospitalization for patients undergoing hematopoietic stem cell transplantation (HCT).

  • Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma

    Abstract Full Text
    JAMA. 2016; 315(19):2115-2116. doi: 10.1001/jama.2016.4913

    This JAMA Clinical Guidelines Synopsis summarizes the National Comprehensive Cancer Network’s and European Society of Medical Oncology’s recent recommendations on follow-up imaging in patients in remission from Hodgkin and diffuse large B-cell lymphoma.

  • Elevated Lactate Levels in a Non–Critically Ill Patient

    Abstract Full Text
    JAMA. 2015; 313(8):849-850. doi: 10.1001/jama.2014.14074
  • Knowing HIV Status Crucial in Cancer Treatment

    Abstract Full Text
    JAMA. 2015; 313(7):660-660. doi: 10.1001/jama.2015.238
  • Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma

    Abstract Full Text
    JAMA. 2014; 312(23):2505-2507. doi: 10.1001/jama.2014.16095

    This Editorial discusses the optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma.

  • Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007

    Abstract Full Text
    free access
    JAMA. 2011; 305(14):1450-1459. doi: 10.1001/jama.2011.396
  • JAMA January 5, 2011

    Figure 6: MicroRNA/TP53 Pathogenetic Model for Human CLL

    A novel pathogenetic model for chronic lymphocytic leukemia (CLL) showing a pathway of microRNAs and protein coding genes that are involved in the development of CLL. The microRNA 15a (miR-15a)/microRNA 16-1 (miR-16-1) cluster, the microRNA 34b (miR-34b)/microRNA 34c (miR-34c) cluster, and the genes tumor protein p53 (TP53), B-cell CLL/lymphoma 2 (BCL2), myeloid cell leukemia sequence 1 (BCL2-related) (MCL1), and zeta-chain (TCR)–associated protein kinase 70kDa (ZAP70) are the main partners in this model. mRNA indicates messenger RNA.
  • JAMA January 5, 2011

    Figure 1: Targeting of TP53 by miR-15a and miR-16 and Effects on TP53 Downstream Effectors in Cell Lines and Primary B-Cell Chronic Lymphocytic Leukemia (B-CLL) Samples

    A, Immunoblots showing the protein expression of tumor protein p53 (TP53), B-cell CLL/lymphoma 2 (BCL2), and vinculin (VCL) in MEG-01 cells transfected with microRNA 15a (miR-15a), microRNA 16 (miR-16), their combination, or their antisense oligonucleotides. Cotransfection of miR-15a and miR-16-1 was performed at the same concentration of oligonucleotides per each; therefore, the total amount of transfected microRNAs was doubled with respect to the other lanes. VCL is the normalization standard used to normalize the amount of proteins loaded to each well. The numbers above the blots indicate the intensity of the band expressed as a ratio “gene product (TP53 or BCL2)/VCL” and normalized to “scrambled.” B, Immunoblots showing the protein expression of TP53, cyclin-dependent kinase inhibitor 1A (p21, Cip 1) (CDKN1A), BCL2 binding component 3 (BBC3), BCL2, zeta-chain (TCR)–associated protein minase 70 kDa (ZAP70), and VCL in primary B-cell CLL cells of 3 patients with CLL with a homozygous 13q deletion. Primary leukemic cells were stably infected with a lentiviral vector expressing miR-15a (LV- miR-15a), a lentiviral vector expressing miR-16-1 (LV- miR-16), or an empty lentiviral vector (LV-Empty). VCL is the normalization standard used to normalize the amount of proteins loaded to each well. The numbers above the blots indicate the intensity of the band expressed as ratio “gene product (TP53, CDKN1A, BBC3, BCL2 or ZAP70)/VCL” and normalized to “LV-Empty.”
  • JAMA January 5, 2011

    Figure 4: Transactivation of MicroRNA miR-16 Affecting Expression of miR-16 Targets

    A, Northern blots showing messenger RNA (mRNA) expression of microRNA 16 (miR-16) and immunoblots showing the protein expression of tumor protein p53 (TP53), B-cell CLL/lymphoma 2 (BCL2), caspase 3, apoptosis-related cysteine peptidase (CASP3), and vinculin (VCL) in K562 leukemic cells 24 or 48 hours after transfection with an empty or TP53-expressing vector (TP53). VCL is the normalization standard used to normalize the amount of proteins loaded to each well. The numbers above the blots indicate the intensity of the band expressed as ratio “gene product (TP53, BCL2 or CASP3)/VCL” and normalized to “empty.” B, Immunoblots showing the protein expression of TP53 and VCL, and the Northern blots showing mRNA expression of miR-16 and RNA, U6 small nuclear 1 (RNU6-1), after doxorubicin-induced TP53 activation in MEG-01 cells. VCL and RNU6-1 are the normalization standards used to normalize the amount of proteins and RNA loaded to each well, respectively. The numbers above the blots indicate the intensity of the band expressed as ratio “TP53/VCL” or “ miR-16/RNU6-1 ” and normalized to untreated cells (left panels) and to anti-CTRL treated cells (right panels).
  • JAMA April 28, 2010

    Figure: Trends in the Use of Imaging Modalities by Selected Cancer Types

    The vertical axis indicates the percentage of patients who received 1 or more of the imaging procedures within 2 years of diagnosis. Trends are shown separately for patients diagnosed with breast cancer, colorectal cancer, leukemia, lung cancer, lymphoma, or prostate cancer.
  • Anaplastic Large-Cell Lymphoma in Women With Breast Implants

    Abstract Full Text
    free access
    JAMA. 2008; 300(17):2030-2035. doi: 10.1001/jama.2008.585
  • Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies

    Abstract Full Text
    JAMA. 2008; 299(5):510-512. doi: 10.1001/jama.299.5.510
  • Lymphoma

    Abstract Full Text
    JAMA. 2007; 297(18):2044-2044. doi: 10.1001/jama.297.18.2044